论文部分内容阅读
采用国产司帕沙星 (sparfloxacin)与洛美沙星 (lomefloxacin)随机对照治疗呼吸道、泌尿道、皮肤软组织急性细菌性感染及淋球菌性尿道炎。共 2 0 2例 ,试验组 10 2例 ,对照组 10 0例 ,司帕沙星 2 0 0 mg,每日 1次 ,洛美沙星 2 0 0 mg或 30 0 mg每日 2次 ,疗程 5～ 14d。两组的痊愈率与有效率分别为 79.41%与 91.18%及6 8.0 0 %与 84.0 0 % ;两组细菌阳性率、清除率及阴转率分别为 95 .1%、93%、92 .7%及 94%、86 .45 %、87.2 3% ,以上结果经统计学处理均无显著性差异。临床分离的 196株致病菌对司帕沙星、洛美沙星、氧氟沙星、环丙沙星及依诺沙星的高敏率分别为 86 .77%、79.5 9%、79.0 8%、83.16 %及 6 1.2 2 % ,司帕沙星与后四者比较 ,除与依诺沙星有显著性差异 (P<0 .0 5 )外 ,与其余 3种无显著性差异 (P>0 .0 5 )。以上 5种抗菌药物对196株致病菌的 MIC结果提示 :司帕沙星对金葡球菌及大肠埃希氏菌的 MIC5 0 及 MIC90 低于其他 4种喹诺酮类抗菌药物 ,对其他革兰氏阳性菌及阴性菌的 MIC值较其他 4种喹诺酮类抗菌药略低或相似。两组的不良反应发生率分别为 4.85 %和 3.96 % ,经统计学处理差异无显著性。以上结果提示司帕沙星抗菌谱广、抗菌活性强、安全有效、使用简便。
Acute bacterial infections of the respiratory tract, urinary tract, skin and soft tissue, and gonococcal urethritis were treated with a domestic control of sparfloxacin and lomefloxacin. A total of 202 cases, the experimental group of 102 cases of the control group of 100 cases, sparfloxacin 200 mg, day 1, lomefloxacin 200 mg or 30 0 mg twice daily treatment 5 ~ 14d. The cure rate and effective rate of the two groups were 79.41% and 91.18%, respectively, and 68.0% and 84.0% respectively. The positive rate, clearance rate and negative conversion rate of the two groups were 95.1%, 93% and 92.7 % And 94%, 86.45%, 87.2 3%, the results were statistically no significant difference. The high sensitivity of 196 pathogenic bacteria isolates to sparfloxacin, lomefloxacin, ofloxacin, ciprofloxacin and enoxacin were 86.77%, 79.59% and 79.0 8% respectively, 83.16%, and 6 1.2 2% respectively. There was no significant difference between sparfloxacin and the latter four except for enrofloxacin (P <0.05) (P> 0 05) .0 5). MIC of the above five kinds of antibacterials to 196 pathogenic bacteria indicated that the MIC50 and MIC90 of sparfloxacin against Staphylococcus aureus and Escherichia coli were lower than the other four quinolone antibacterial drugs, MIC of positive and negative bacteria is slightly lower than or similar to the other four quinolone antibiotics. The incidence of adverse reactions in both groups were 4.85% and 3.96%, respectively, with no significant difference by statistical analysis. The above results suggest sparfloxacin antibacterial spectrum wide, strong antibacterial activity, safe and effective, easy to use.